Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 2,801.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 15,000 shares of the medical equipment provider’s stock after acquiring an additional 14,483 shares during the period. Clal Insurance Enterprises Holdings Ltd’s holdings in Boston Scientific were worth $655,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of BSX. Perigon Wealth Management LLC bought a new position in Boston Scientific during the second quarter worth $883,000. Y Intercept Hong Kong Ltd lifted its position in shares of Boston Scientific by 148.8% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after buying an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in Boston Scientific in the second quarter worth about $3,253,000. PensionDanmark Pensionsforsikringsaktieselskab raised its stake in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after acquiring an additional 28,961 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in Boston Scientific in the 2nd quarter worth approximately $38,539,000. 89.07% of the stock is currently owned by institutional investors.
Boston Scientific Stock Performance
BSX opened at $41.96 on Friday. The company has a 50 day simple moving average of $43.83 and a two-hundred day simple moving average of $53.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.81. Boston Scientific Corporation has a 1-year low of $39.57 and a 1-year high of $101.91. The firm has a market cap of $60.82 billion, a P/E ratio of 17.78, a PEG ratio of 1.29 and a beta of 0.60.
Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. Boston Scientific’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.75 earnings per share. Equities analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the company. UBS Group dropped their price objective on Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a research note on Thursday, October 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Boston Scientific in a report on Friday, October 2nd. Piper Sandler lowered their price objective on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, July 29th. Robert W. Baird boosted their price target on Boston Scientific from $50.00 to $51.00 and gave the stock an “outperform” rating in a research report on Thursday, October 29th. Finally, Canaccord Genuity Group cut their price target on shares of Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $61.43.
Check Out Our Latest Stock Analysis on BSX
Boston Scientific Company Profile
Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
